Accès ouvert · CC BY

Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma

Article scientifique 2019 Sciences de la santé Anglais

Résumé

Abstract Background The upregulated expression of the JAK/STAT pathway promotes tumor growth in Hodgkin lymphoma (HL) and primary mediastinal large B-cell lymphoma (PMBCL). Based on the hypothesis that JAK2 is a therapeutic target, we performed a prospective pilot study using ruxolitinib. Methods Relapsed or refractory patients with HL or PMBCL were eligible for this study, and JAK2 amplification was assessed by fluorescence in situ hybridization. Ruxolitinib was administered orally at a dose of 20 mg twice daily for a 28-day cycle. Treatment was continued for up to 16 cycles or until progressive disease or intolerability. The primary objective was to assess the overall disease control rate comprising complete response (CR), partial response (PR), or stable disease (SD). Results We analyzed 13 HL patients and six PMBCL patients. All responders (one CR, five PR, and one SD) had HL whereas all cases of PMBCL progressed after first or second cycle. The disease control rate for HL was 54% (7/13) with median response duration of 5.6 months. JAK2 amplification was present in six of nine patients tested (four HL, two PMBCL), and three of these HL patients showed PR (n = 2) or SD (n = 1). None of the three HL patients shown to not have JAK2 amplification responded to ruxolitinib. Most treatment-related adverse events were grade 1 or 2 and manageable. Conclusions Ruxolitinib has single-agent activity against HL but does not act against PMBCL with or without JAK2 amplification.

Citer ce document

Kim, S. J., Yoon, D. H., Kang, H. J., Hong, J. Y., Lee, H. S., Oh, S. Y., Shin, H., Kong, J. H., Yi, J. H., Sakamoto, K., Ko, Y. H., Huh, J., Lee, S., Takeuchi, K., Shin, D., Suh, C., & Kim, W. S. (2019). Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma. Research Square. https://doi.org/10.21203/rs.2.11081/v3

Exporter : BibTeX · RIS (Zotero, Mendeley, EndNote)

Accès au document

Texte intégral archivé sur SPHAERO, en accès ouvert : lisible gratuitement en ligne après connexion. Le document reste aussi disponible à sa source. Se connecter

Voir l'article sur le site de la revue

Licence et provenance

Licence : CC BY

Notice moissonnée depuis OpenAlex le 03/09/2026. Le document reste hébergé par sa source.
Voir le document à la source →

Autres versions

Statistiques

Consultations (hors robots) : 17

Téléchargements (hors robots) : 0

Méthode de comptage